Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix

Early Phase 1

Active, not recruiting

• Conditions: Covid19
• Interventions: Biological: COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use

• Registration Number: NCT03305341
• Lead Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Brief Summary

Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients with controlled cancers.

1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains.

2. Activate Human Antigen Presentation Reaction to COVID-19 Specific Antigen.

3. The human antigen presenting cells (APCs) can take up and process COVID-19 target antigen protein into small peptide fragments, and then COVID-19 virus can be killed by APCs directly.

Detailed Description

* Conducting an initial small, controlled trial to assess therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients with controlled cancers.

* 20 Moderate COVID-19 patients with controlled cancers

* Moderate COVID-19

* Positive testing by standard RT-PCR assay or equivalent testing

* Symptoms of moderate illness with COVID-19, which could include any symptom of mild illness or shortness of breath with exertion

* Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (SpO2) \> 93% on room air at sea level, heart rate ≥ 90 beats per minute

* No clinical signs indicative of Severe or Critical Illness Severity

* Novavax COVID-19 Vaccine 1.0 mL plus BCG Organism 50 MG Mix

* By the percutaneous route with the multiple puncture device

* Negative testing COVID-19 by standard RT-PCR assay or equivalent testing after injection 3 weeks.

* Positive IGRA blood test with COVID-19 spike protein antigen after percutaneous use 21 days.

* Our trial duration will be 4 weeks.

Study Timeline

• Study First Submitted: 2017-10-04
• Study First Submitted QC: 2017-10-04
• Study First Posted: 2017-10-09
• Study Start: 2025-05-18
• Status Verified: 2025-06
• Last Update Submitted: 2025-06-06
• Last Update Posted: 2025-06-11
• Primary Completion: 2026-07-18
• Study Completion: 2026-07-28

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Controlled Cancers
• Moderate COVID-19
• Positive testing by standard RT-PCR assay or equivalent testing
• Symptoms of moderate illness with COVID-19, which could include any symptom of mild illness or shortness of breath with exertion
• Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (SpO2) > 93% on room air at sea level, heart rate ≥ 90 beats per minute
• No clinical signs indicative of Severe or Critical Illness Severity

Exclusion Criteria

• 1. Uncontrolled Cancers
• 2. Severe or Critical Illness Severity
• 3. Pregnancy
• 4. Breast-feeding
• 5. The patients with other serious inter-current illness
• 6. Serious Allergy
• 7. Serious Bleed Tendency
• 8. The prohibition of the biological product

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Assess for therapeutic biologics activity (proof-of-concept)	COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use	Therapeutic Biological Product Mix activity - NOVAVAX COVID-19 VACCINE 1.0 mL add into BCG Organism 50 MG

Primary Outcome Measures

Name	Time	Method
Number of Participants with Moderate COVID-19:	Duration at least 28 days	* 20 Moderate COVID-19 patients with controlled cancers; * Moderate COVID-19; * Positive testing by standard RT-PCR assay; * Symptoms of moderate illness with COVID-19, which could include any symptom of mild illness or shortness of breath with exertion; * Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (SpO2) \> 93% on room air at sea level, heart rate ≥ 90 beats per minute; * No clinical signs indicative of Severe or Critical Illness Severity
Rate of Positive COVID-19 nucleic acid:	Duration at least 28 days	* 20 Moderate COVID-19 patients with controled cancers; * Positive testing COVID-19 by standard RT-PCR assay immediately; * COVID-19 nucleic acid testing, assessed by RT-PCR Assay Kit; * Rate of Positive COVID-19 nucleic acid must be 100%
Rate of Negative COVID-19 nucleic acid	Duration at least 28 days	* 20 Moderate COVID-19 patients with controlled cancers; * NOVAVAX COVID-19 VACCINE 1.0 mL plus BCG Organism 50 MG Mix; * By the percutaneous route with the multiple puncture device; * Negative COVID-19 by standard RT-PCR assay after percutaneous use 3 weeks; * COVID-19 nucleic acid testing, assessed by RT-PCR Assay Kit; * Rate of Negative COVID-19 nucleic acid will be more than 80%
20 COVID-19 Participants with IGRA blood test with COVID-19 spike protein antigen	Duration at least 28 days	Positive IGRA blood test with COVID-19 spike protein antigen after percutaneous use 21 days
20 COVID-19 Participants with IGRA blood test with TB antigens	Duration at least 28 days	* Negative IGRA blood test with TB antigens before percutaneous use; * Positive IGRA blood test with TB antigens after percutaneous use 21 days

Trial Locations

Locations (1)

Medicine Invention Design Incorporation (MIDI) - IORG0007849; 🇺🇸 North Bethesda, Maryland, United States